Editorial

Abstract

Global cancer incidence is going to increase almost 50% within the next two decades with a predicted rise to 28.4 million new cases in 2040^[1]. Although cancer survivorship could be improved for all entities to over 60% between 2010 to 2020^[2], malignancies of the gastrointestinal (GI) system are becoming an even greater problem. In fact, out of the 10 million cancer deaths observed in 2020 more than 40% of them are due to gastrointestinal malignancies including cancers of the esophagus, stomach, liver, pancreas, colon, and rectum¹. In particular, pancreatic cancer is predicted to overtake colorectal, prostate, and breast cancer to rank as the second place in cancer related deaths in 2030^[3].